Kidney Transplantation - Pipeline Review, H1 2016

  • ID: 3720441
  • Report
  • 176 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Amgen Inc.
  • Bio-inRen
  • Digna Biotech, S.L.
  • FibroGen, Inc.
  • Hansa Medical AB
  • Pharming Group N.V.
  • MORE
Kidney Transplantation - Pipeline Review, H1 2016

Summary

‘Kidney Transplantation - Pipeline Review, H1 2016’, provides an overview of the Kidney Transplantation pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Kidney Transplantation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Kidney Transplantation and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Kidney Transplantation
- The report reviews pipeline therapeutics for Kidney Transplantation by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Kidney Transplantation therapeutics and enlists all their major and minor projects
- The report assesses Kidney Transplantation therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Kidney Transplantation

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Kidney Transplantation
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Kidney Transplantation pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Amgen Inc.
  • Bio-inRen
  • Digna Biotech, S.L.
  • FibroGen, Inc.
  • Hansa Medical AB
  • Pharming Group N.V.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Kidney Transplantation Overview

Therapeutics Development

Pipeline Products for Kidney Transplantation – Overview

Pipeline Products for Kidney Transplantation – Comparative Analysis

Kidney Transplantation – Therapeutics under Development by Companies

Kidney Transplantation – Therapeutics under Investigation by Universities/Institutes

Kidney Transplantation – Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Unknown Stage Products

Kidney Transplantation – Products under Development by Companies

Kidney Transplantation – Products under Investigation by Universities/Institutes

Kidney Transplantation – Companies Involved in Therapeutics Development

Alexion Pharmaceuticals, Inc.

Amgen Inc.

Amyndas Pharmaceuticals LLC

Angion Biomedica Corp.

Astellas Pharma Inc.

Bio-inRen

Catalyst Biosciences, Inc.

Corline Biomedical AB

CSL Limited

Digna Biotech, S.L.

Dompe Farmaceutici S.p.A.

Effimune SAS

FibroGen, Inc.

GlaxoSmithKline Plc

Grifols, S.A.

Hansa Medical AB

Kyowa Hakko Kirin Co., Ltd.

Mabtech Limited

Noorik Biopharmaceuticals AG

Novartis AG

Opsona Therapeutics Limited

Pharming Group N.V.

Prolong Pharmaceuticals, LLC

Quark Pharmaceuticals, Inc.

Shire Plc

t-cell Europe GmbH

Tiziana Life Sciences Plc

Zyrnat Biotherapeutics SL

Kidney Transplantation – Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

albumin (human) - Drug Profile

Product Description

Mechanism of Action

R&D Progress

AMY-101 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

AS-2521780 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

basiliximab biobetter - Drug Profile

Product Description

Mechanism of Action

R&D Progress

BB-3 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

belimumab - Drug Profile

Product Description

Mechanism of Action

R&D Progress

bleselumab - Drug Profile

Product Description

Mechanism of Action

R&D Progress

BRN-1889 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

C1 esterase inhibitor (human) - Drug Profile

Product Description

Mechanism of Action

R&D Progress

C1 esterase inhibitor (human) - Drug Profile

Product Description

Mechanism of Action

R&D Progress

C1 esterase inhibitor (recombinant) - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Cardiotrophin-1 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

carfilzomib - Drug Profile

Product Description

Mechanism of Action

R&D Progress

CB-2782 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Cellular Immunotherapy for Kidney Transplant - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Cellular Immunotherapy for Kidney Transplantation - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Cellular Immunotherapy for Kidney Transplantation - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Cellular Immunotherapy for Multiple Sclerosis and Kidney Transplantation - Drug Profile

Product Description

Mechanism of Action

R&D Progress

CFZ-533 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

eculizumab - Drug Profile

Product Description

Mechanism of Action

R&D Progress

EFFI-7H - Drug Profile

Product Description

Mechanism of Action

R&D Progress

FCR-001 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

FG-4497 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

foralumab - Drug Profile

Product Description

Mechanism of Action

R&D Progress

FR-104 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

FX-06 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Monoclonal Antibody to Inhibit CD47 for Cardiovascular Disease, Kidney Transplantation and Oncology - Drug Profile

Product Description

Mechanism of Action

R&D Progress

MRX-109 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

N-003 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

OPN-305 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

QPI-1002 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Recombinant Enzyme to Inhibit Immunoglobulin G for Kidney Transplantation - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Renaparin - Drug Profile

Product Description

Mechanism of Action

R&D Progress

reparixin - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Sanguinate - Drug Profile

Product Description

Mechanism of Action

R&D Progress

TNT-009 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

ZY-11 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Kidney Transplantation – Recent Pipeline Updates

Kidney Transplantation - Dormant Projects

Kidney Transplantation – Discontinued Products

Kidney Transplantation – Product Development Milestones

Featured News & Press Releases

Apr 04, 2016: FDA clears Hansa Medical’s IND application for IdeS in kidney transplantation

Mar 11, 2016: Study results presented in New England Journal of Medicine strengthen Hansa Medical belief in the potential of IdeS

Dec 07, 2015: True North Therapeutics Presents Data in Patients with Cold Agglutinin Disease Supporting Patient Profiles for TNT009 Phase 1b Study

Nov 13, 2015: Data shows that one dose of IdeS has favorable effect and completely removes HLA-antibodies

Nov 10, 2015: Data showing that IdeS can silence memory B-cells published in Journal of Immunology

Oct 30, 2015: Licensee's drug to commence Phase 2 and Phase 3 trials

Oct 13, 2015: Shire's CINRYZE (C1 esterase inhibitor [human]) Receives FDA Fast Track Designation for Investigation in the Treatment of Antibody Mediated Rejection in Patients Receiving Kidney Transplants

Sep 15, 2015: Data from Hansa Medical’s First Phase II study of IdeS in Sensitized Kidney Transplantation Patients Presented in Oral Session at ESOT 2015

Sep 14, 2015: Hansa Medical receives FDA Orphan Drug Designation for IdeS

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Kidney Transplantation, H1 2016

Number of Products under Development for Kidney Transplantation – Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Number of Products under Development by Companies, H1 2016 (Contd..1)

Number of Products under Investigation by Universities/Institutes, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Development, H1 2016

Comparative Analysis by Unknown Stage Development, H1 2016

Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016 (Contd..1)

Products under Investigation by Universities/Institutes, H1 2016

Kidney Transplantation – Pipeline by Alexion Pharmaceuticals, Inc., H1 2016

Kidney Transplantation – Pipeline by Amgen Inc., H1 2016

Kidney Transplantation – Pipeline by Amyndas Pharmaceuticals LLC, H1 2016

Kidney Transplantation – Pipeline by Angion Biomedica Corp., H1 2016

Kidney Transplantation – Pipeline by Astellas Pharma Inc., H1 2016

Kidney Transplantation – Pipeline by Bio-inRen, H1 2016

Kidney Transplantation – Pipeline by Catalyst Biosciences, Inc., H1 2016

Kidney Transplantation – Pipeline by Corline Biomedical AB, H1 2016

Kidney Transplantation – Pipeline by CSL Limited, H1 2016

Kidney Transplantation – Pipeline by Digna Biotech, S.L., H1 2016

Kidney Transplantation – Pipeline by Dompe Farmaceutici S.p.A., H1 2016

Kidney Transplantation – Pipeline by Effimune SAS, H1 2016

Kidney Transplantation – Pipeline by FibroGen, Inc., H1 2016

Kidney Transplantation – Pipeline by GlaxoSmithKline Plc, H1 2016

Kidney Transplantation – Pipeline by Grifols, S.A., H1 2016

Kidney Transplantation – Pipeline by Hansa Medical AB, H1 2016

Kidney Transplantation – Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2016

Kidney Transplantation – Pipeline by Mabtech Limited, H1 2016

Kidney Transplantation – Pipeline by Noorik Biopharmaceuticals AG, H1 2016

Kidney Transplantation – Pipeline by Novartis AG, H1 2016

Kidney Transplantation – Pipeline by Opsona Therapeutics Limited, H1 2016

Kidney Transplantation – Pipeline by Pharming Group N.V., H1 2016

Kidney Transplantation – Pipeline by Prolong Pharmaceuticals, LLC, H1 2016

Kidney Transplantation – Pipeline by Quark Pharmaceuticals, Inc., H1 2016

Kidney Transplantation – Pipeline by Shire Plc, H1 2016

Kidney Transplantation – Pipeline by t-cell Europe GmbH, H1 2016

Kidney Transplantation – Pipeline by Tiziana Life Sciences Plc, H1 2016

Kidney Transplantation – Pipeline by Zyrnat Biotherapeutics SL, H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Stage and Target, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Kidney Transplantation Therapeutics – Recent Pipeline Updates, H1 2016

Kidney Transplantation – Dormant Projects, H1 2016

Kidney Transplantation – Dormant Projects (Contd..1), H1 2016

Kidney Transplantation – Dormant Projects (Contd..2), H1 2016

Kidney Transplantation – Discontinued Products, H1 2016

List of Figures

Number of Products under Development for Kidney Transplantation, H1 2016

Number of Products under Development for Kidney Transplantation – Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Top 10 Targets, H1 2016

Number of Products by Stage and Top 10 Targets, H1 2016

Number of Products by Top 10 Mechanism of Actions, H1 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Top 10 Molecule Types, H1 2016

Number of Products by Stage and Top 10 Molecule Types, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
Alexion Pharmaceuticals, Inc.
Amgen Inc.
Amyndas Pharmaceuticals LLC
Angion Biomedica Corp.
Astellas Pharma Inc.
Bio-inRen
Catalyst Biosciences, Inc.
Corline Biomedical AB
CSL Limited
Digna Biotech, S.L.
Dompe Farmaceutici S.p.A.
Effimune SAS
FibroGen, Inc.
GlaxoSmithKline Plc
Grifols, S.A.
Hansa Medical AB
Kyowa Hakko Kirin Co., Ltd.
Mabtech Limited
Noorik Biopharmaceuticals AG
Novartis AG
Opsona Therapeutics Limited
Pharming Group N.V.
Prolong Pharmaceuticals, LLC
Quark Pharmaceuticals, Inc.
Shire Plc
t-cell Europe GmbH
Tiziana Life Sciences Plc
Zyrnat Biotherapeutics SL
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll